ING Groep NV Purchases 7,324 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ING Groep NV increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 33.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,085 shares of the biopharmaceutical company’s stock after purchasing an additional 7,324 shares during the period. ING Groep NV’s holdings in Regeneron Pharmaceuticals were worth $20,718,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. Fairfield Financial Advisors LTD bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $37,000. Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $39,000. Finally, Valley Wealth Managers Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $49,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 1.5 %

Shares of REGN opened at $696.02 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a 50-day moving average of $700.02 and a 200 day moving average of $886.33. The firm has a market capitalization of $76.09 billion, a price-to-earnings ratio of 18.18, a PEG ratio of 2.30 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the business posted $11.86 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.51%.

Analyst Ratings Changes

REGN has been the topic of several recent analyst reports. Bank of America restated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price for the company. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Finally, UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.